ALPS Advisors’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-78,782
| Closed | -$121K | – | 1026 |
|
|
2025
Q1 | $121K | Buy |
78,782
+21,022
| +36% | +$32.2K | ﹤0.01% | 976 |
|
|
2024
Q4 | $143K | Buy |
+57,760
| New | +$143K | ﹤0.01% | 982 |
|
|
2023
Q4 | – | Sell |
-52,222
| Closed | -$358K | – | 961 |
|
|
2023
Q3 | $358K | Buy |
52,222
+269
| +0.5% | +$1.84K | ﹤0.01% | 646 |
|
|
2023
Q2 | $539K | Buy |
51,953
+8,017
| +18% | +$83.1K | ﹤0.01% | 600 |
|
|
2023
Q1 | $355K | Sell |
43,936
-1,269
| -3% | -$10.3K | ﹤0.01% | 672 |
|
|
2022
Q4 | $712K | Buy |
+45,205
| New | +$712K | 0.01% | 533 |
|
|
2018
Q4 | – | Sell |
-54,824
| Closed | -$796K | – | 871 |
|
|
2018
Q3 | $796K | Buy |
54,824
+9,977
| +22% | +$145K | 0.01% | 445 |
|
|
2018
Q2 | $896K | Buy |
44,847
+3,478
| +8% | +$69.5K | 0.01% | 357 |
|
|
2018
Q1 | $725K | Buy |
41,369
+7,201
| +21% | +$126K | 0.01% | 372 |
|
|
2017
Q4 | $843K | Buy |
34,168
+4,626
| +16% | +$114K | 0.01% | 293 |
|
|
2017
Q3 | $762K | Buy |
29,542
+5,413
| +22% | +$140K | 0.01% | 289 |
|
|
2017
Q2 | $654K | Buy |
24,129
+1,718
| +8% | +$46.6K | ﹤0.01% | 313 |
|
|
2017
Q1 | $668K | Sell |
22,411
-2,021
| -8% | -$60.2K | ﹤0.01% | 261 |
|
|
2016
Q4 | $663K | Buy |
+24,432
| New | +$663K | ﹤0.01% | 251 |
|